SUZHOU

Adagene to Present at Investor Conferences in June

Retrieved on: 
Mercoledì, Maggio 22, 2024
SAN, ADAG

SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024.

Key Points: 
  • SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024.
  • Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide a company update, including progress on the masked, anti-CTLA-4 SAFEbody® ADG126.
  • Company management will also host investor meetings.
  • A live webcast of the presentations will also be accessible in the Investors section of the company’s website at https://www.adagene.com .

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Venerdì, Marzo 29, 2024
Head, Immunotherapy, HNSCC, Patient, Roche, Lead, Immunoglobulin G, Neoplasm, CRC, Audit committee, PD-1, Observation, Bioinformatics, Colorectal cancer, SAN, Information technology, Pembrolizumab, PRS, Safety, PD-L1, Compensated emancipation, Annual report, Apoptosis, Cervical cancer, Part, Merck, Senior, Bevacizumab, MSS, GAAP, ASCO, PFS, MTD, Liver disease, HCC, Therapeutic index, Endometrial cancer, Progression-free survival, ADS, Net, Regulatory T cell, Research and development, Liver, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the full year 2023 and provided corporate updates.

Key Points: 
  • Both confirmed PRs are sustained after more than one year with repeat dosing while maintaining robust safety profiles.
  • Observation of these clinical activities triggered further expansion into the second stage of the Simon’s 2-stage design for this dose level.
  • Net loss attributable to Adagene Inc.’s shareholders was US$18.9 million for the year ended December 31, 2023, compared to US$80.0 million in 2022.
  • The company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Retrieved on: 
Giovedì, Marzo 7, 2024
SAN, Neoplasm, Division, Research fellow, Immunotherapy, Colorectal cancer, Gastrointestinal cancer, Drug development, Mentorship, Clinical research, Pembrolizumab, CRC, MSS, National Cancer Institute, FACP, Preventive healthcare, Gene expression, NCCN, USC, Associate, Patient, Harvard Medical School, Oncology, George Washington University, Cancer, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).

Key Points: 
  • SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).
  • Dr. Lenz accelerates translational and clinical research and provides training and mentoring in the design and implementation of investigator-initiated trials.
  • In 1991, he completed his internship, residency, and fellowship training at the Eberhardt Karls Universität in Tübingen, Germany.
  • “His insight and clinical experience as a leading expert in colorectal cancer is of great importance as we develop our SAFEbody® ADG126 for patients worldwide.”
    For more information about members of the Adagene Scientific and Strategic Advisory Board, visit: https://www.adagene.com/about/key-advisors/

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Retrieved on: 
Martedì, Febbraio 27, 2024
SAN, Conference

SAN DIEGO and SUZHOU, China, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in the Leerink Partners Global Biopharma Conference 2024, taking place March 11-13 in Miami, Florida.

Key Points: 
  • SAN DIEGO and SUZHOU, China, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in the Leerink Partners Global Biopharma Conference 2024, taking place March 11-13 in Miami, Florida.
  • Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide an update on its masked, anti-CTLA-4 SAFEbody® ADG126, including key milestones for 2024.
  • Company management will also host investor meetings.

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl

Retrieved on: 
Venerdì, Febbraio 9, 2024
SAN, CRC, FDA, Part, MSS, Safety, Colorectal cancer, Pembrolizumab, Merck, Patient, CDE, Merck & Co., Pharmaceutical industry

SAN DIEGO and SUZHOU, China, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced progress and expansion of the clinical collaboration development program for its masked, anti-CTLA-4 SAFEbody, ADG126 in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC).

Key Points: 
  • Given the safety profile of ADG126, Adagene has also initiated evaluation of 20 mg/kg loading doses in combination with pembrolizumab in patients with advanced/metastatic cancer.
  • The company plans dose expansion with this regimen in patients with MSS CRC in the US and Asia Pacific.
  • Adagene has also received clearance from the CDE in China to initiate clinical evaluation of ADG126 in combination with pembrolizumab.
  • Data from the ongoing phase 1b/2 clinical trial of ADG126 in combination with pembrolizumab, including dose expansion cohorts, are anticipated throughout 2024:
    Evaluation of 20 mg/kg loading doses for Project Optimus requirements:

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Retrieved on: 
Martedì, Gennaio 16, 2024
Endometrial cancer, Patient, Therapy, Associate, MD, City, MSS, SAN, Liver disease, ASCO, Merck & Co., Poster, Stage 2, Clinical research, Society, Research fellow, Immunotherapy, FACP, Cervical cancer, PRS, PFS, Safety, Liver, Observation, CRC, Pembrolizumab, NCCC, Merck, Physician, Oncology, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data from its presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.

Key Points: 
  • “These promising data support further evaluation of this potential best-in-class anti-CTLA-4 antibody, ADG126, in combination with pembrolizumab for MSS CRC patients, including battling new liver lesions in those patients initially without detectable liver metastasis.
  • One of the patients had PD-1 refractory cervical cancer and the other had endometrial cancer.
  • The durable clinical activity of ADG126 in combination with pembrolizumab will continue to be evaluated as a larger cohort of subjects becomes evaluable at the 10 mg/kg Q3W dose level.
  • The clinical profile of ADG126 in combination with pembrolizumab presents a great opportunity for MSS CRC patients that otherwise have limited immunotherapy options available.”

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

Retrieved on: 
Giovedì, Gennaio 4, 2024
Immunotherapy, CRC, ASCO, MSS, SAN, Society, Publication, Poster, Interim, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.

Key Points: 
  • - Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-limited efficacy challenges with this proven immunotherapy target -
    SAN DIEGO and SUZHOU, China, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.
  • Details for the poster include:
    The presentation is embargoed until 5:00 p.m. Eastern Time on January 16 and will subsequently be made available on the Publications page of the company’s website here .
  • * As of this press release, muzastotug is used as the non-proprietary name for ADG126.

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

Retrieved on: 
Venerdì, Novembre 3, 2023
Neoplasm, Bevacizumab, FOLFOX, MSS, Trae tha Truth, FOLFIRI, Society for Immunotherapy of Cancer, Pembrolizumab, Therapeutic index, SITC, Immunotherapy, CRC, Liver disease, Annual general meeting, Tumor microenvironment, Safety, Society, TME, Patient, PR, Pharmaceutical industry, Ipilimumab

SAN DIEGO and SUZHOU, China, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today presented new data on its masked, anti-CTLA-4 SAFEbody ADG126 at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting taking place in San Diego. The poster presentation, Optimal Dose Selection of ADG126 (Masked Anti-CTLA-4 SAFEbody®) with Significantly Widened Therapeutic Index Compared to Ipilimumab in Combination with anti-PD-1 Antibodies Informed by QSP Modeling, is available on the company’s website.

Key Points: 
  • The poster presentation, Optimal Dose Selection of ADG126 (Masked Anti-CTLA-4 SAFEbody®) with Significantly Widened Therapeutic Index Compared to Ipilimumab in Combination with anti-PD-1 Antibodies Informed by QSP Modeling , is available on the company’s website.
  • The data, which integrate clinical results with physiologically based pharmacokinetic and quantitative systems pharmacology modeling, demonstrated that Adagene’s lead SAFEbody candidate, ADG126, is effective at targeting CTLA-4 within the tumor microenvironment (TME).
  • ADG126 SAFEbody is the most advanced clinical stage anti-CTLA-4 candidate integrating masking technology and Treg depletion for superior safety and efficacy profiles.
  • A phase 2 dose expansion cohort is ongoing to evaluate ADG126 plus pembrolizumab in patients with MSS CRC without liver metastases.

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on: 
Giovedì, Ottobre 12, 2023
Annual general meeting, SITC, Poster, SAN, Rare-earth element, Paint, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its poster presentation at the SITC 38th Annual Meeting taking place November 1-5, 2023 in San Diego.

Key Points: 
  • SAN DIEGO and SUZHOU, China, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its poster presentation at the SITC 38th Annual Meeting taking place November 1-5, 2023 in San Diego.
  • Details for the poster include:

Espace Technology Unveils Cutting-Edge "Morphling" Cyberflex Gaming Chair with Dynamic Lumbar Support

Retrieved on: 
Mercoledì, Settembre 20, 2023
3D, Habit, Neck, Fatigue, Movement, Video game, Furniture

LOS ANGELES, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Espace Technology, a trailblazing gaming peripheral manufacturer, is thrilled to announce the launch of its latest innovation - the Morphling Cyberflex Gaming Chair.

Key Points: 
  • LOS ANGELES, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Espace Technology, a trailblazing gaming peripheral manufacturer, is thrilled to announce the launch of its latest innovation - the Morphling Cyberflex Gaming Chair.
  • Designed with gamers in mind, this revolutionary chair redefines comfort and performance, setting a new standard in the gaming chair industry.
  • The Morphling Cyberflex Gaming Chair is a game-changer, boasting an ingenious dynamic 3D lumbar support system that adapts seamlessly to the user's movements.
  • No matter if you're leaning left, right, forward, or backward, this chair maintains an unwavering level of support and comfort.